Standardized application of poly ADP-ribose polymerase inhibitors in maintenance therapy of ovarian cancer

VernacularTitle:PARP抑制剂在卵巢癌维持治疗中的规范化应用
Author: Anfeng LI ¹ ; Dongxu ZHAO ; Jiayin GAO ; Xiaohong QIU
Author Information

1. 哈尔滨医科大学附属第二医院妇产科　150081
Keywords: Ovarian neoplasms; Poly (ADP-ribose) polymerase inhibitors; Biological markers; Maintenance treatment
From: Journal of Chinese Physician 2021;23(12):1918-1920,F3
CountryChina
Language:Chinese
Abstract: Ovarian cancer is a common gynecological malignancy and the most common cause of cancer death. Ovarian cancer is usually treated with surgery combined with chemotherapy as the preferred treatment. In recent years, with the continuous development of medical technology and the in-depth research on ovarian cancer at home and abroad, the molecular targeted therapy of ovarian cancer has received extensive attention. Among them, the poly ADP-ribose polymerase (PARP) inhibitors have made great breakthroughs and advances in the precise and standardized treatment of ovarian cancer. This paper discusses the study of PARP inhibitors in sensitivity biomarkers of ovarian cancer, and reviews the standardized treatment of PARP inhibitors in maintenance therapy of ovarian cancer.